Search
AEOL-10150
go.drugbank.com/drugs/DB05874ExperimentalAEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
ISIS 14803
go.drugbank.com/drugs/DB05803InvestigationalISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits
Sulesomab
go.drugbank.com/drugs/DB13976ApprovedMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Categories: Amino Acids, Peptides, and Proteins, Inflammation and Infection DetectionLitifilimab
go.drugbank.com/drugs/DB18864InvestigationalSCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy). … Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (
AT1022
go.drugbank.com/drugs/DB04995ExperimentalAT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect. … AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.
PYM50018
go.drugbank.com/drugs/DB05126ExperimentalWhen administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle strength and extends survival time. … In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in vitro.
HY10275
go.drugbank.com/drugs/DB05079ExperimentalHY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. … This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought to account for the compounds excellent efficacy and tolerability profile.
Selenomethionine Se-75
go.drugbank.com/drugs/DB09400ApprovedCategories: Amino Acids, Peptides, and ProteinsAmdoxovir
go.drugbank.com/drugs/DB06619InvestigationalCategories: Nucleic Acids, Nucleotides, and NucleosidesRelmapirazin
go.drugbank.com/drugs/DB19130Investigationalin Normal and Renal Compromised Subjects). … Relmapirazin is under investigation in clinical trial NCT05425719 (Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the Medibeacon Transdermal GFR Measurement System in Evaluation of Kidney Function